Routman David M, Yan Elizabeth, Vora Sujay, Peterson Jennifer, Mahajan Anita, Chaichana Kaisorn L, Laack Nadia, Brown Paul D, Parney Ian F, Burns Terry C, Trifiletti Daniel M
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, United States.
Department of Radiation Oncology, Mayo Clinic, Phoenix, AZ, United States.
Front Neurol. 2018 Nov 13;9:959. doi: 10.3389/fneur.2018.00959. eCollection 2018.
Stereotactic radiosurgery (SRS) is increasingly utilized to treat the resection cavity following resection of brain metastases and recent randomized trials have confirmed postoperative SRS as a standard of care. Postoperative SRS for resected brain metastases improves local control compared to observation, while also preserving neurocognitive function in comparison to whole brain radiation therapy (WBRT). However, even with surgery and SRS, rates of local recurrence at 1 year may be as high as 40%, especially for larger cavities, and there is also a known risk of leptomeningeal disease after surgery. Additional treatment strategies are needed to improve control while maintaining or decreasing the toxicity profile associated with treatment. Preoperative SRS is discussed here as one such approach. Preoperative SRS allows for contouring of an intact metastasis, as opposed to an irregularly shaped surgical cavity in the post-op setting. Delivering SRS prior to surgery may also allow for a "sterilizing" effect, with the potential to increase tumor control by decreasing intra-operative seeding of viable tumor cells beyond the treated cavity, and decreasing risk of leptomeningeal disease. Because there is no need to treat brain surrounding tumor in the preoperative setting, and since the majority of the high dose volume can then be resected at surgery, the rate of symptomatic radiation necrosis may also be reduced with preoperative SRS. In this mini review, we explore the potential benefits and risks of preoperative vs. postoperative SRS for brain metastases as well as the existing literature to date, including published outcomes with preoperative SRS.
立体定向放射外科(SRS)越来越多地用于治疗脑转移瘤切除术后的切除腔,最近的随机试验已证实术后SRS是一种标准治疗方法。与观察相比,切除脑转移瘤后的术后SRS可改善局部控制,同时与全脑放疗(WBRT)相比还能保留神经认知功能。然而,即使进行了手术和SRS,1年时的局部复发率仍可能高达40%,尤其是对于较大的腔隙,并且手术后还存在已知的软脑膜疾病风险。需要额外的治疗策略来改善控制,同时维持或降低与治疗相关的毒性。术前SRS作为一种这样的方法在此进行讨论。术前SRS允许对完整的转移瘤进行轮廓勾画,这与术后设置中不规则形状的手术腔不同。在手术前进行SRS也可能产生“杀菌”效果,有可能通过减少手术中活肿瘤细胞在治疗腔外的播种来提高肿瘤控制,并降低软脑膜疾病的风险。由于在术前设置中无需治疗肿瘤周围的脑组织,并且由于大部分高剂量体积随后可在手术中切除,术前SRS还可能降低有症状的放射性坏死发生率。在本综述中,我们探讨了术前与术后SRS治疗脑转移瘤的潜在益处和风险以及迄今为止的现有文献,包括术前SRS已发表的结果。